Anavex Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-39.95	-46.38	-43	-47.51	-47.98	-37.91
Stock-Based Compensation	10.6	11.55	9.44	16.37	18.38	8.23
Other Operating Activities	-	-	-	0.85	-	-
Change in Accounts Payable	-1.93	-5.38	5.31	0.5	-0.91	0.75
Change in Unearned Revenue	-0.02	-0.04	-0.08	0.47	-	0.44
Change in Other Net Operating Assets	-2.78	1.2	-2.48	1.54	6.28	-1.9
Operating Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Issuance of Common Stock	47.76	12.14	11.98	29.65	22	158.79
Repurchase of Common Stock	-2.71	-2.71	-	-	-	-
Other Financing Activities	-	-	-	-	-0.71	-5.55
Financing Cash Flow	45.05	9.43	11.98	29.65	21.29	153.24
Net Cash Flow	10.97	-29.61	-18.84	1.87	-2.95	122.86
Cash Income Tax Paid	0.12	0.13	0.3	0.14	0.33	0.14
Levered Free Cash Flow	-21.83	-24.39	-19.43	-14.28	-6.03	-15.9
Unlevered Free Cash Flow	-21.83	-24.39	-19.43	-14.28	-6.03	-15.9
Change in Working Capital	-4.73	-4.22	2.75	2.51	5.36	-0.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.